Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.
Pulse Biosciences Inc. (PLSE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Portolan Capital Management George Mccabe | 102,197 | $1,808,887 | 0.1% | |
| 2. | Citadel Investment Group Ken Griffin | 37,118 | $656,989 | +177% | 0% |
| 3. | Panoramic Capital William R. Hazen | 35,996 | $637,129 | +37% | 0.29% |
| 4. | 24,000 | $424,800 | -29% | 0% | |
| 5. | ExodusPoint Capital Michael Gelband | 21,864 | $386,993 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.41 | 145,140 | $2,091,467.40 | 47,709,140 | 2024-09-12 | Filing | |
| $14.77 | 12,800 | $189,056.00 | 47,564,000 | 2024-09-11 | Filing | |
| $14.66 | 34,659 | $508,100.94 | 47,551,200 | 2025-09-10 | Filing | |
| $17.18 | 55,256 | $949,298.08 | 42,328,717 | 2024-12-13 | Filing | |
| $17.13 | 45,404 | $777,770.52 | 42,273,461 | 2024-12-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.53 | 4,600 | $85,238.00 | 43,298 | 2025-10-02 | Filing | |
| $18.48 | 400 | $7,392.00 | 43,298 | 2025-09-19 | Filing | |
| $18.49 | 20,000 | $369,800.00 | 43,298 | 2025-09-18 | Filing | |
| $16.21 | 20,000 | $324,200.00 | 122,872 | 2025-09-17 | Filing | |
| $16.28 | 25,000 | $407,000.00 | 122,872 | 2025-09-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 66,326 | $910,659 | 0.15% | |
| 2. | 28,156 | $386,582 | 0.23% | |
| 3. | 20,373 | $279,721 | 0% | |
| 4. | 15,905 | $218,376 | 0.01% | |
| 5. | 107 | $1,469 | 0% |
News See All
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial
Pulse Biosciences, Inc. (NASDAQ:PLSE) is advancing bioelectric medicine through its proprietary Nano-Pulse Stimulation (NPS) technology, targeting immuno-oncology, dermatology, and cardiac ablation.
12 Healthcare Stocks with Insider Buying in 2025
In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, with divergent trends in technology adoption, investment, and fundraising.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. Hello, and welcome to the Pulse Biosciences Second Quarter 2025 Earnings Conference Call. Please note that this call is being recorded.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences First Quarter 2025 Financial Results Conference Call. At this time all lines are in listen-only mode.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Louella, and I will be your conference operator today.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Pulse Biosciences First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
5 ChatGPT Penny Stock Picks Right Now
Pulse Biosciences, Inc. (NASDAQ:PLSE) is using its exclusive technologies to treat heart diseases. The stock is up 33% over the past one year. Earlier this month Pulse Biosciences, Inc.